Vial assemblies and vial assembly systems

By combining the vial assembly and the radiation shielding assembly, the operation steps are simplified and the infusion efficiency is improved, solving the problems of complicated operation and high error rate in the existing technology, and ensuring the complete infusion of radioactive microspheres.

CN224975630UActive Publication Date: 2026-11-17JIANGSU MEDNOVO MEDICAL GRP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202522579430.X
Authority / Receiving Office
CN · China
Patent Type
Utility models(China)
Current Assignee / Owner
Filing Date
2025-12-04
Publication Date
2026-11-17
Estimated Expiration
2035-12-04

AI Technical Summary

Technical Problem

Existing radioactive microsphere infusion systems have complicated operating procedures and are prone to errors, especially when the microspheres are nearly empty, requiring manual adjustment of the injection needle to ensure that all microspheres are infused into the body.

Method used

A vial assembly and vial assembly system were designed, including a vial, a sealing block and a puncture needle. The fluid blockage and fluid connectivity states can be switched by longitudinally moving the puncture needle. Combined with a radiation shielding component, the operation process is simplified, and microsphere infusion can be completed with only one puncture needle.

Benefits of technology

It simplifies the operation process, reduces the error rate, improves infusion efficiency, reduces surgical time and radiation risk to medical staff, and ensures complete infusion of microspheres.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN224975630U_ABST
    Figure CN224975630U_ABST
Patent Text Reader

Abstract

This invention provides a vial assembly and a vial assembly system. The vial assembly includes a vial, a sealing block, and a puncture needle. The vial has a body and a top seal. The body has an upper opening, a drug-containing chamber, and a bottom channel. The top seal seals the opening. The bottom channel communicates with the drug-containing chamber and contains a sealing block to prevent drug leakage. The puncture needle is longitudinally movable within the bottom channel. The vial assembly has two states: fluid blocking and fluid communication. When the puncture needle does not pierce the sealing block, the assembly is in a fluid blocking state; when the puncture needle pierces the sealing block, it communicates with the drug-containing chamber, and the assembly enters a fluid communication state. The vial assembly system is composed of a radiation shielding assembly and a vial assembly. This invention simplifies user operation and reduces the error rate.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure relates to components of a medical device for radioembolization, and more specifically, to a vial assembly for containing radioactive microspheres and a vial assembly system comprising the vial assembly. Background Technology

[0002] Radioembolization, also known as selective internal radiation therapy (SIRT), is used to treat primary or metastatic malignant liver tumors. In SIRT, radiolabeled microspheres are injected into the patient's hepatic artery. Due to increased angiogenesis in the liver tumor, the radiolabeled microspheres preferentially accumulate within the tumor. The radiolabeled microspheres decay and deliver radiation to surrounding tissues.

[0003] Existing microsphere infusion system reference Figure 1 Its main principle is to inject water into a conical-bottom bottle containing resin microspheres, and then use pressure to deliver the microspheres into the human body. Specifically, syringe SA contains water for injection, syringe SB contains contrast agent, and syringe SC is used to inject either water for injection or air into the conical-bottom bottle.

[0004] Manually operate the three-way valve VB on the infusion box to connect the LA and LB lines. Manually open the three-way valve VA and inject water for injection, contrast agent, and then water for injection sequentially through syringes SA and SB, respectively. The water for injection is to prevent the microspheres from mixing with the contrast agent. Manually operate the three-way valve VB on the infusion box to connect the LA and LC lines. Syringe SC, connected to the LD line, injects water for injection into the conical-bottom bottle V, which mixes the microspheres and then infuses them into the patient through the LC and LA lines.

[0005] When the microspheres in the conical-bottom bottle are nearly empty, air needs to be injected into the bottle using syringe SC to ensure all microspheres are infused into the patient. This typically involves first opening the infusion box cap, raising the needle connected to the LD tubing, and pushing the needle connected to the LC tubing down to the conical bottom area. Then, the LA and LC tubings are connected via the three-way valve VB on the infusion box, allowing air to be injected into syringe SC to infuse all the microspheres into the patient. This procedure is overly complicated and prone to errors. Utility Model Content

[0006] To address the problems in the prior art, this utility model provides a medicine bottle assembly and a medicine bottle assembly system.

[0007] In a first aspect, a vial assembly includes a vial, a sealing block, and a puncture needle. The vial includes a body and a top seal. The body has an upper opening, a drug-containing chamber, and a bottom channel. The top seal is configured to engage with the body from the upper opening to provide a seal to the drug-containing chamber. The bottom channel extends from below the drug-containing chamber outwards and is in fluid communication with the drug-containing chamber. The sealing block is disposed in the bottom channel to prevent the substance stored in the drug-containing chamber from flowing out of the bottom channel. The puncture needle is longitudinally movably disposed within the bottom channel. The vial assembly has a fluid-blocking state and a fluid-connecting state. When the puncture needle does not puncture the sealing block, the puncture needle is not in communication with the drug-containing chamber, and the vial assembly is in a fluid-blocking state. When the puncture needle moves longitudinally to puncture the sealing block and is in fluid communication with the drug-containing chamber, the vial assembly is in a fluid-connecting state.

[0008] In particular, the bottom of the drug-containing chamber is constructed in a cone shape that is wider at the top and narrower at the bottom.

[0009] Preferably, the puncture needle is provided with a stop block, which is configured to restrict the longitudinal movement of the puncture needle; wherein, when the puncture needle punctures the sealing block and is in fluid communication with the drug receiving chamber, the stop block abuts against the bottle body or the sealing block.

[0010] Preferably, the bottle bottom channel includes a first cavity and a first actuation auxiliary cavity. The first cavity is located on the side of the first actuation auxiliary cavity away from the drug-containing chamber, and the inner diameter of the first cavity is smaller than the inner diameter of the first actuation auxiliary cavity. A sealing block is fixedly disposed at the upper end of the first actuation auxiliary cavity, and a stop block is longitudinally movable within the first actuation auxiliary cavity. When the puncture needle punctures the sealing block and enters fluid communication with the drug-containing chamber, the stop block abuts against the sealing block.

[0011] Preferably, the bottle bottom channel further includes a second cavity, which is disposed between the drug receiving chamber and the first actuation auxiliary chamber; the inner diameter of the second cavity is smaller than the inner diameter of the first actuation auxiliary chamber, and the first actuation auxiliary chamber is connected to the drug receiving chamber through the second cavity.

[0012] Secondly, a vial assembly system includes a radiation shielding assembly and the vial assembly described in the first aspect. The radiation shielding assembly includes a shielding body and a silicone component. The shielding body has a top opening and a vial receiving cavity. The radiation shielding assembly is configured to receive a vial within the vial receiving cavity through the top opening. A mating channel is provided at the bottom of the vial receiving cavity, communicating with a channel at the bottom of the vial. The mating channel includes a notch and a receiving groove from top to bottom. The receiving groove has a shape consistent with the silicone component, which is seated within the receiving groove and seals the notch. When the vial assembly and the radiation shielding assembly are in the assembled position, the vial assembly is in fluid communication, and the non-puncture end of the puncture needle passes through the notch and the silicone component and extends below the receiving groove. Preferably, a linear cut is provided in the middle of the silicone component.

[0013] Preferably, the mating channel further includes a second actuation auxiliary cavity, which is located below the receiving groove; when the vial assembly and the radiation shielding assembly are in the assembled position, the non-puncture end of the puncture needle enters the second actuation auxiliary cavity.

[0014] Preferably, the second actuation auxiliary cavity includes an upper cavity and a lower cavity that are longitudinally connected. The inner diameter of the upper cavity is larger than the outer diameter of the non-puncture end of the puncture needle, and the inner diameter of the lower cavity is smaller than the outer diameter of the non-puncture end of the puncture needle. When the vial assembly and the radiation shielding assembly are in the assembled position, the non-puncture end of the puncture needle abuts against the bottom of the upper cavity.

[0015] Preferably, the bottom of the shielding body is provided with an external connection channel, which is connected to the second actuation auxiliary cavity, and the outlet of the external connection channel is provided with a pipeline interface; the radiation shielding assembly also includes a straight-through valve, which is fluidly connected to the pipeline interface.

[0016] The features and advantages of this utility model include:

[0017] When using the vial assembly provided in this disclosure to deliver drugs, only a needle is needed to pierce the top of the vial and enter the vial. Thus, when the vial is nearly empty of microspheres, the step of adjusting the injection needle during infusion can be eliminated. It is even possible to directly inject air into the vial using the first syringe to deliver all the radioactive microspheres into the body. This invention simplifies the operation and reduces the error rate. Attached Figure Description

[0018] To more clearly illustrate the technical solutions in the embodiments of this disclosure, the accompanying drawings used in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments of this disclosure. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0019] Figure 1This illustrates a prior art radiopharmaceutical delivery system;

[0020] Figure 2 The following are examples of radioactive microsphere delivery systems;

[0021] Figure 3A A perspective view of the vial assembly of some embodiments is shown;

[0022] Figure 3B A partial sectional view of a medicine bottle assembly according to some embodiments is shown;

[0023] Figure 3C It shows Figure 3B Enlarged schematic diagram of some states at point M1, where the vial assembly is in a fluid-blocked state;

[0024] Figure 3D It shows Figure 3B Enlarged schematic diagram of some other states at M1, in which the vial assembly is in a fluid communication state;

[0025] Figure 4A An exploded perspective view of a radiation shielding assembly in some embodiments is shown;

[0026] Figure 4B A three-dimensional cross-sectional schematic diagram of a radiation shielding assembly according to some embodiments is shown;

[0027] Figure 4C It shows Figure 4B Enlarged view of point M2;

[0028] Figure 4D It shows Figure 4C The diagram shows the silicone parts removed.

[0029] Figure 5A A perspective view of a vial assembly system is shown for some embodiments, the vial assembly system being composed of vial assemblies and radiation shielding assemblies;

[0030] Figure 5B A partial sectional view of a medicine bottle assembly system according to some embodiments is shown;

[0031] Figure 6A An exploded partial sectional view of a vial assembly system in several embodiments is shown, illustrating the assembly process of the vial assembly and the radiation shielding assembly;

[0032] Figure 6B A partial three-dimensional cross-sectional view of a vial assembly system is shown in some embodiments, illustrating some assembly states of the vial assembly and radiation shielding assembly, wherein the vial assembly is in a fluid-blocking state;

[0033] Figure 6C It shows Figure 6B Enlarged view of point M3;

[0034] Figure 6D A partial sectional view of a vial assembly system in some embodiments is shown, illustrating that the vial assembly is in fluid communication and that the vial assembly and radiation shielding assembly are in the assembled position.

[0035] Figure 6E It shows Figure 6D Enlarged view of point M4;

[0036] Figure 7A A three-dimensional schematic diagram of a radiopharmaceutical delivery device is shown for some embodiments;

[0037] Figure 7B A three-dimensional partial cross-sectional view of the internal arrangement of a radiopharmaceutical delivery device, illustrating some embodiments, is shown. Detailed Implementation

[0038] The technical solutions of the embodiments of this disclosure will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of this disclosure, and not all embodiments. Based on the embodiments of this disclosure, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of this disclosure.

[0039] This disclosure relates to components, systems, and methods for delivering radioactive microspheres or other related elements. The system may include a drug delivery device for delivering microspheres to a patient via a conduit configuration, a vial assembly system, a radiation shielding assembly, a vial assembly, and a vial for containing the microspheres. Furthermore, this document discloses methods for safely and effectively assembling vial assemblies and radiation shielding assemblies, and for infusing drugs to a patient via components, parts, or devices in an operating system.

[0040] Radioactive microspheres can be made of ceramic or polymeric materials, such as glass microspheres, resin microspheres, etc. In some embodiments, the microspheres used are spherical in shape and have a diameter of about 5–100 μm (e.g., 20–80 μm, 30–50 μm, or about 35 μm). Typically, these microspheres can be delivered using a carrier fluid via an embolized microcatheter. The carrier fluid can be sterile water. Microspheres are denser than the carrier fluid, so when the carrier fluid is at rest, the microspheres tend to settle at the bottom of the container (vial) containing the carrier fluid and microspheres. Therefore, during infusion, the microspheres need to be dispersed or redispersed in the carrier fluid so that they can be delivered through the catheter.

[0041] Figure 2An embodiment of an infusion system 10 for delivering microspheres is shown. System 10 may include a first syringe 20, a second syringe 40, a vial 11, a three-way stopcock valve 60, and a lever 62. The first syringe 20 is connected to the vial 11 containing the microspheres via a first tubing 22, and the vial 11 is connected to the three-way stopcock valve 60 via a second tubing 24. The second syringe 40 is connected to the three-way stopcock valve 60 via a fourth tubing 42. The three-way stopcock valve 60 is connected to the patient via a third tubing 26 (a microcatheter line) and a microcatheter 80. The three-way stopcock valve 60 is operated by the lever 62, allowing the third tubing 26 to selectively connect to either the second tubing 24 or the fourth tubing 42.

[0042] A fluid connection is formed between the first syringe 20, the first tube 22, and the vial 11, which connects to the interior of the vial 11 via the top of the vial 11. A fluid connection is formed between the vial 11, the second tube 24, and the three-way stopcock valve 60, which connects to the interior of the vial 11 via the bottom of the vial 11.

[0043] The substances in the first syringe 20 and the second syringe 40 may be the same or different. The substance in the first syringe 20 may be the same or different at different times. The substance in the second syringe 40 may be the same or different at different times. In some cases, both the substances in the first syringe 20 and the second syringe 40 are sterile water. In some cases, the substance in the first syringe 20 is sterile water, and the substance in the second syringe 40 is a contrast agent. In some cases, the substance in the first syringe 20 is air. In some embodiments, the sterile water delivered to vial 11 can disperse the microspheres and deliver them to the patient through the second tube 24, the third tube 26, and the microcatheter 80.

[0044] In some embodiments, the vial 11 further includes a top seal 112. Optionally, the top seal 112 is a removable cap. Optionally, the top seal 112 is a diaphragm that can be punctured with a needle, for example, to insert microspheres into the vial by puncturing the diaphragm with a needle. Preferably, the top seal 112 is a rubber stopper, which is secured to the vial body 111 with an aluminum cap, preventing the rubber stopper from being removed from the vial body 111, and allowing microspheres to be inserted into the vial by puncturing the rubber stopper with a needle.

[0045] System 10 may include a housing 70, which may be used to hold some of the various components of system 10 therein and to provide shielding for the operator during use of system 10. Housing 70 may include transparent portions to allow observation of the components and may also include opaque portions for radiation protection of the operator. In some embodiments, housing 70 is made of a material including a radiation-opaque material, such as acrylic, wherein the thickness is sufficient to attenuate at least about 50% of radiation emitted from anywhere within the housing (such as vial 11) and from the first tube 22, second tube 24, third tube 26, and fourth tube 42. Other materials may also be coated on housing 70 or used in the construction of other containers within it. For example, housing 70 may contain a high-Z material such as lead. As another example, a shield may be added inside housing 70 to accommodate vial 11.

[0046] A portion of the first tube 22, a portion of the fourth tube 42, a portion of the third tube 26, the second tube 24, the vial 11, and the three-way stopcock valve 60 can be enclosed within the housing 70. One end of the lever 62 is connected to the three-way stopcock valve 60, the middle portion is supported and fixed by other components disposed inside the housing 70, and the other end extends to the outside of the housing 70. Optionally, the end of the lever 62 located outside the housing 70 is coupled to an operating knob 64, through which the operator controls the rotation of the lever 62.

[0047] During operation, the first syringe 20 and the second syringe 40 are used alternately to deliver the microspheres to the patient in multiple small equal portions within a predetermined time (e.g., 20 minutes). The operator can periodically check the position of the microcatheter 80 to ensure that it remains in the correct position during the delivery procedure and to confirm that blood is flowing forward without stagnation.

[0048] In some implementations, when the contents of vial 11 are plentiful, sterile water is used through the first syringe 20 and the first tube 22 to disperse the microspheres in vial 11 and discharge them through the second tube 24; when the microspheres in vial 11 are almost empty, air can be used through the first syringe 20 to expel the microspheres from vial 11 to empty the tubing.

[0049] In other embodiments, the entire process of transporting the microspheres in vial 11 is carried out by the first syringe 20 using air to enter vial 11 from the first tube 22, and the microspheres are discharged through the second tube 24 by the air.

[0050] It should be added that the fourth tube 42 can also be connected to two syringes via a second three-way valve, for example, see reference. Figure 1The arrangement of valve VA, syringe SA, and syringe SB is such that one syringe is used for infusing sterile water, and the other syringe is used for infusing contrast agent. Both syringes can be selectively connected to a three-way stopcock valve 60 via a second three-way valve.

[0051] refer to Figures 3A to 3D This disclosure provides one or more embodiments of a vial assembly 110. The vial assembly 110 includes a vial 11, a sealing block 12, and a puncture needle 13. The vial 11 includes a body 111 and a top seal 112. The body 111 has an upper opening 113, a drug-containing chamber 114, and a bottom channel 115. The top seal 112 engages with the body 111 from the upper opening 113 and provides a seal to the drug-containing chamber 114. The bottom channel 115 originates at the bottom of the drug-containing chamber 114 and extends outward from the drug-containing chamber 114, and is in fluid communication with the drug-containing chamber 114. The sealing block 12 is disposed in the bottom channel 115 to prevent the substance stored in the drug-containing chamber 114 from flowing out of the bottom channel 115, and provides a seal to the drug-containing chamber 114. The puncture needle 13 is longitudinally movable within the bottom channel 115 of the vial (see...). Figure 3C The vial assembly 110 is positioned in the H direction to allow the sealing block 12 to be punctured by the puncture needle 13. The vial assembly 110 has both a fluid-blocking state and a fluid-connecting state. When the puncture needle 13 does not puncture the sealing block 12, the puncture needle 13 is not in communication with the drug-containing chamber 114, and the vial assembly 110 is in the fluid-blocking state. When the puncture needle 13 moves longitudinally to puncture the sealing block 12 and establishes fluid communication with the drug-containing chamber 114, the vial assembly 110 is in the fluid-connecting state. In some embodiments, the bottom 107 of the drug-containing chamber is configured as a cone (V-shape) that is wider at the top and narrower at the bottom to facilitate the discharge of the drug solution.

[0052] Preferably, the puncture needle 13 is provided with a stop 16, which is configured to limit the longitudinal movement of the puncture needle 13. The puncture needle 13 and the stop 16 can be an integral structure or two separate components fixedly connected by bonding or welding. Optionally, the longitudinal movement of the stop 16 is restricted to the outside of the bottle bottom channel 115, for example, the outer bottom of the bottle body 111, when the puncture needle 13 punctures the sealing block 12, the puncture needle 13 moves until the stop 16 abuts against the outer bottom of the bottle body 111.

[0053] Preferably, refer to Figure 3C and Figure 3DThe longitudinal movement of the stop 16 is restricted within the bottom channel 115. When the puncture needle 13 punctures the sealing block 12, the puncture needle 13 moves until the stop 16 abuts against the sealing block 12 in the bottom channel 115. In some embodiments, the sealing block 12 is made of rubber to provide frictional resistance during the opening process. Specifically, the puncture needle 13 is arranged longitudinally on the side of the sealing block 12 away from the drug-containing chamber 114, with the puncture end 117 of the puncture needle close to the sealing block 12, and the non-puncture end 118 of the puncture needle extending along the bottom channel 115 to the outer bottom of the vial 11 (e.g., Figure 3A (As shown). In some embodiments, the non-puncture end 118 of the puncture needle extends along the bottom channel 115 of the vial, but does not protrude beyond the bottom of the vial 11. For example, the bottom of the vial 11 has a recess, and the non-puncture end 118 extends into the recess or is flush with the bottom of the vial 11.

[0054] Specifically, in some implementation schemes, reference is made to Figures 3B to 3D The bottle bottom channel 115 includes a first actuation auxiliary cavity 14 and a first cavity 501, with the first cavity 501 located on the side of the first actuation auxiliary cavity 14 away from the drug receiving chamber 114. The inner diameter of the first cavity 501 is smaller than the inner diameter of the first actuation auxiliary cavity 14. A sealing block 12 is fixedly disposed at the upper end 105 of the first actuation auxiliary cavity, and a stop block 16 is longitudinally movably arranged within the first actuation auxiliary cavity 14. Optionally, the bottle bottom channel 115 further includes a second cavity 502, which is disposed between the drug receiving chamber 114 and the first actuation auxiliary cavity 14. The inner diameter of the second cavity 502 is smaller than the inner diameter of the first actuation auxiliary cavity 14, and the first actuation auxiliary cavity 14 is connected to the drug receiving chamber 114 through the second cavity 502.

[0055] Please refer to the above. Figures 6B to 6E The size and / or shape of the stop 16 are configured to be disposed in the first actuation auxiliary cavity 14. During the upward movement of the puncture needle 13 to pierce the sealing block 12, when the stop 16 reaches the upper end 105 of the first actuation auxiliary cavity, the stop 16 is adapted to be blocked by the sealing block 12 and the top wall of the first actuation auxiliary cavity 14, preventing the puncture needle 13 from continuing to move upward. Preferably, the cross-sectional shape of the stop 16 is the same as the cross-sectional shape of the sealing block 12, for example, both are circular. Preferably, the depth of the first actuation auxiliary cavity 14 is greater than the thickness of the sealing block 12; and, before the sealing block 12 is pierced, referring to 3C and... Figure 6C The initial position of the stop block 16 is set at the lower end 106 of the first actuation auxiliary cavity, and the initial position of the puncture end 117 of the puncture needle is set near the bottom of the sealing block 12, thereby ensuring that the puncture needle 13 obtains sufficient longitudinal movement distance, can completely puncture the sealing block 12 and fluidly communicate with the drug receiving chamber 114.

[0056] In some embodiments, the non-puncture end 118 of the puncture needle is configured to puncture the sealing block 12 when subjected to an upward longitudinal force. Optionally, this upward longitudinal force is applied directly by the operator or by the reaction force of other components in contact with the non-puncture end 118 of the puncture needle. After the sealing block 12 is punctured, the puncture needle 13 is in fluid communication with the drug-containing chamber 114.

[0057] refer to Figures 4A to 4D This disclosure also provides one or more embodiments of a radiation shielding assembly 130. The radiation shielding assembly 130 is used to shield a vial assembly 110 containing a radiopharmaceutical. The radiation shielding assembly 130 includes a shielding body 31 and a silicone element 33. The shielding body 31 has a top opening 131 and a vial receiving cavity 132, through which the radiation shielding assembly 130 can receive the vial assembly 110 within the vial receiving cavity 132. Optionally, in some embodiments, the radiation shielding assembly 130 further includes a top cover 139, which engages with the top opening 131 via a protrusion and groove. For example, the top cover 139 has a wedge-shaped protrusion with an inclined upper surface that slopes downwards along the tightening direction; a groove has an inclined mating surface adapted to engage with the upper surface of the wedge-shaped protrusion.

[0058] The bottom of the vial receiving cavity 132 is provided with a mating channel 401. When the vial assembly 110 and the radiation shielding assembly 130 are in the assembled position, the mating channel 401 communicates with the vial bottom channel 115. The mating channel 401 includes a notch section 134 and a receiving groove 133 from top to bottom. The silicone part 33 has the same shape as the receiving groove 133, and the silicone part 33 is located in the receiving groove 133 and seals the notch section 134. When the vial assembly 110 and the radiation shielding assembly 130 are in the assembled position, the vial assembly 110 is in a fluid communication state; at this time, the puncture end 117 of the puncture needle punctures the sealing block 12, and the non-puncture end 118 of the puncture needle passes through the notch section 134 and the silicone part 33 and extends to the bottom of the receiving groove 13. Preferably, a straight, linear incision 138 can be provided in the middle of the silicone part 33. The straight, linear incision 138 can not only guide and assist the non-puncture end 118 of the puncture needle to pass smoothly through the silicone part 33, but also has a good sealing effect.

[0059] Preferably, the mating channel 401 further includes a second actuation auxiliary cavity 135, which is located below the receiving groove 133. When the radiation shielding assembly 130 and the vial assembly 110 are assembled, that is, when the two are in the assembled position, the non-puncture end 118 of the puncture needle passes through the silicone part 33 and specifically enters the second actuation auxiliary cavity 135.

[0060] Specifically, refer to Figure 4D The second actuation auxiliary cavity 135 includes an upper cavity 136 and a lower cavity 137 that are longitudinally connected. The inner diameter of the upper cavity 136 is larger than the outer diameter of the non-puncture end 118 of the puncture needle, and the inner diameter of the lower cavity 137 is smaller than the outer diameter of the non-puncture end 118 of the puncture needle. When the radiation shielding assembly 130 and the vial assembly 110 are assembled, that is, when the two are in the assembled position, the non-puncture end 118 of the puncture needle abuts against the bottom of the upper cavity 136.

[0061] Further, refer to Figure 4A and Figure 4B The bottom of the shielding body 31 is also provided with an external connection channel 121, which communicates with the mating channel 401. In other words, the bottom connection channel 121 is itself part of the mating channel 401; that is, the mating channel 401 also includes the external connection channel 121, which is located below and communicates with the second actuation auxiliary cavity 135. The radiation shielding assembly 130 also includes a straight-through valve 32, and a pipeline interface 122 is provided at the outlet of the external connection channel 121. The straight-through valve 32 is fluidly connected to the pipeline interface 122. When the radiation shielding assembly 130 and the vial assembly 110 are assembled, i.e., when they are in the assembled position, the straight-through valve 32 is fluidly connected to the pipeline interface 122, the external connection channel 121, the puncture needle 13, and the drug receiving chamber 114. During the assembly of the radiation shielding assembly 130 and the vial assembly 110, the straight-through valve 32 remains closed to prevent the drug in the vial 11 containing the radiation microspheres from flowing out.

[0062] It should be added that, in some embodiments, when the bottom of the vial 11 is provided with a recess, and the non-puncture end 118 extends into the recess or is flush with the bottom of the vial 11, the bottom of the vial receiving cavity 132 is provided with a matching protrusion, and the mating channel 401 starts from the protrusion.

[0063] This disclosure also provides a vial assembly system 150, referring to Figure 5, which includes the aforementioned vial assembly 110 and radiation shielding assembly 130. (See Figure 5 for reference.) Figures 6A to 6E The following describes the assembly steps of the vial assembly 110 and the radiation shielding assembly 130 according to some embodiments. First, the vial assembly 110 is inserted into the vial receiving cavity 132 through the top opening 131 of the shielding body 31; then, the puncture process is completed in the following two stages.

[0064] First stage reference Figure 6BPressing down on vial 11, the non-puncture end 118 of the puncture needle passes through the silicone part 33 and reaches the bottom of the upper cavity 136 of the second actuation auxiliary cavity 135. The non-puncture end 118 of the puncture needle is restricted by the aperture of the lower cavity 137 and cannot continue to enter the lower cavity 137, that is, the non-puncture end 118 abuts against the bottom of the upper cavity 136. At the end of the first stage, the position of the stop block 16 in the first actuation auxiliary cavity 14 changes little, and the puncture end 117 of the puncture needle only partially punctures the sealing block 12 or does not puncture the sealing block 12 (see reference). Figure 3C and Figure 6C ).

[0065] Second stage reference Figure 6D Continue pressing the vial 11. The non-puncture end 118 of the puncture needle is subjected to an upward reaction force from the bottom of the upper cavity 136 inside the second auxiliary actuation chamber 135, pushing the puncture needle 13 to pierce the sealing block 12, thus establishing fluid communication between the puncture needle 13 and the drug-containing chamber 114. At the end of the second stage, the position of the stop 16 within the first actuation auxiliary chamber 14 changes significantly. The stop 16 moves from the lower end 106 to the upper end 105 of the first actuation auxiliary chamber, and the stop 16 abuts against the sealing block 12 (see reference). Figure 3D and Figure 6E ).

[0066] It should be added that before the vial assembly 110 is assembled into the radiation shielding assembly 130, the puncture needle 13 of the vial assembly 110 can be kept in its initial position by means of a suitable device or packaging method to prevent the puncture needle 13 from puncturing the sealing block 12.

[0067] refer to Figure 7A and Figure 7B This disclosure also provides one or more embodiments of a radiopharmaceutical delivery device 100. The radiopharmaceutical delivery device 100 includes a delivery box 79 and a delivery kit, wherein the delivery kit includes the aforementioned vial assembly system 150, a first tube 22, a second tube 24, a third tube 26, a fourth tube 42, a three-way stopcock valve 60, and a control lever 62.

[0068] The delivery box 79 has a cavity suitable for housing the vial assembly system 150. The delivery box 79 can be a transparent box, such as transparent plastic or glass. The side wall of the delivery box 79 has a first hole 72, a second hole 74 and a third hole 76, the first hole 72 and the second hole 74 are both located on the first side wall 75, the third hole 76 is located on the second side wall 77, and the first side wall 75 and the second side wall 77 are opposite to each other.

[0069] The first end of the first tube 22 extends from the first hole 72 to the outside of the delivery box 79, and the second end of the first tube 22 is connected to the needle body 221. The needle body 221 is configured to enter the interior of the vial 11 from above the vial assembly system 150, through the top opening 131 of the radiation shielding assembly 130, and the upper bottle mouth 113 of the vial assembly 110. The first end of the second tube 24 is fluidly connected to the puncture needle tube 13 of the vial assembly system 150, preferably fluidly connected to the straight-through valve 32, and the second end of the second tube 24 is fluidly connected to the three-way stopcock valve 60. The first end of the third tube 26 is fluidly connected to the three-way stopcock valve 60, and the second end of the third tube 26 extends from the third hole 76 to the outside of the delivery box 79. The first end of the fourth tube 42 extends from the second hole 74 to the outside of the delivery box 79, and the second end of the fourth tube 42 is fluidly connected to the three-way stopcock valve 60.

[0070] The bottom of the cavity of the delivery box 79 is provided with a first mounting seat 71 for mounting the vial assembly system 150. The example first mounting seat 71 is a cylindrical recessed structure adapted to receive the bottom of the shielding body 31 of the radiation shielding assembly 130. A second mounting seat 73 is provided on the inner side of the second sidewall 77 of the delivery box 79 for mounting a three-way stopcock valve 60. The delivery box 79 also has a cover 78, which can be opened or closed relative to the delivery box 79 to facilitate the placement or installation of the delivery kit located within the box.

[0071] One end of the lever 62 is connected to the three-way stopcock valve 60, and the other end passes through the first sidewall 75. Preferably, the conveying device 100 also includes a control knob 64, which is located outside the first sidewall 75 and coupled to the end of the lever 62. The control knob 64 can be used to control the fluid connection switching of the three-way stopcock valve 60 by the lever 62. For example, in some cases, the switching selection is to fluidly connect the fourth pipe 42 and the third pipe 26; in other cases, the switching selection is to fluidly connect the second pipe 24 and the third pipe 26; and in still other cases, the switching selection is to fluidly connect the fourth pipe 42 and the second pipe 24.

[0072] Please refer to the above. Figure 2 , Figure 7A and Figure 7B When delivering microspheres, the radiopharmaceutical delivery device provided in this disclosure can be used according to the following steps.

[0073] (1) Dispense the required injection solution into vials 11.

[0074] (2) Fix the three-way plug valve 60 to the inner wall of the conveying box 79.

[0075] (3) Pass the first tube 22 corresponding to the first hole 72, the fourth tube 42 corresponding to the second hole 74, and the third tube 26 corresponding to the third hole 76 out from the inside of the conveying box 79.

[0076] (4) Connect the first tube 22 to the first syringe 20 containing sterile water, and connect the fourth tube 42 to the second syringe 40 containing sterile water. Fill all tubes with sterile water by injecting the first syringe 20 and the second syringe 40.

[0077] (5) The default connection of the three-way stopcock valve 60 is the third tube 26 and the fourth tube 42. To fill the second tube 24 with sterile water, the control knob 64 needs to be rotated to change the passage of the three-way stopcock valve 60, so that the second tube 24 is connected to the fourth tube 42. At this time, by pushing the second syringe 40, sterile water can flow into the second tube 24 through the three-way stopcock valve 60. Then, control the control knob 64 to rotate back to the initial position (the third tube 26 and the fourth tube 42 are connected).

[0078] (6) Insert the needle 221 connected to the first tube 22 into the small bottle 11 from above, reaching 5 mm below the liquid surface.

[0079] (7) Connect the end of the third tube 26 located outside the delivery box 79 to the patient's body. After successful connection, the control knob 64 can be turned to the "rinse / imaging" position. The fourth tube 42 and the third tube 26 are connected, and the contrast agent is injected through the second syringe 40 of the fourth tube 42.

[0080] (8) After the drug delivery device is fully assembled, close the lid 78 of the delivery box 79, turn the control knob 64 to the "treatment" position, connect the third tube 26 and the second tube 24, and inject sterile water into the vial 11 from the first syringe 20 connected to the first tube 22.

[0081] (9) The operator delivers the medication slowly at a rate of approximately 5 ml per minute. To achieve a slow and controllable delivery rate, the operator can use the first syringe 20 to inject in pulsatile motions of 0.25 ml to 0.5 ml until all the sterile water in the first syringe 20 is used up.

[0082] (10) After all the sterile water in the first syringe 20 has been injected, there is drug residue in the vial 11. In order to reduce drug residue, without moving the needle body 221 connected to the first tube 22, the remaining drug in the vial 11 can be discharged by injecting air into the first tube 22 or by continuing to inject sterile water.

[0083] It should be noted that the vial assembly, vial assembly system, or drug delivery device provided by this utility model can use air to deliver the drug throughout the entire process. That is, in steps (8) to (10) above, the first syringe 20 does not inject sterile water into the vial 11, but injects air so that the drug flows out from the bottom of the vial and then further reaches the human body. When using air injection throughout the entire process, in the operation of step (6) above, the needle body 221 should be inserted 5 mm above the liquid surface.

[0084] The vial assembly, vial assembly system, or drug delivery device disclosed herein has the following beneficial effects.

[0085] Only one puncture needle (needle body 221 in the example) is needed for use. When the microspheres in the vial are nearly empty, the step of adjusting the injection needle during infusion can be eliminated. It is even possible to directly inject air into the vial using the first syringe to deliver all the radioactive microspheres into the body. Therefore, the need for needle changes during surgery is eliminated, surgical time can be shortened, and the radiation risk to medical staff and patients can be reduced.

[0086] Because the fluid outlet channel of the vial assembly is located at the bottom of the vial, regardless of whether the microspheres are injected with air or sterile water (microspheres are heavier than water), the microspheres will inevitably flow out of the vial with the water. Therefore, compared to methods that output the medication from the top of the vial, this invention eliminates the need to monitor microsphere residue inside the vial during infusion, eliminates the need for real-time monitoring of the delivery process, and allows the shielding device to be made of lead material with better shielding performance, thus increasing the shielding effect. Areas through which the radionuclide passes (such as V-shaped vials, straight-through valves, etc.) are made of plastic or silicone rubber, isolating them from lead and preventing bremsstrahlung radiation.

[0087] The above descriptions are merely a few embodiments of this disclosure. Those skilled in the art can make various modifications or variations to the embodiments of this disclosure based on the content disclosed in the application documents without departing from the spirit and scope of this disclosure.

Claims

1. A medicine bottle assembly, characterized in that, include: The vial includes a body and a top seal. The body has an upper opening, a drug-containing chamber, and a bottom channel. The top seal is configured to engage with the body from the upper opening to provide a seal to the drug-containing chamber. The bottom channel extends from below the drug-containing chamber outwards and is in fluid communication with the drug-containing chamber. A sealing block is disposed in the bottom channel of the bottle to prevent the substance stored in the drug receiving chamber from flowing out of the bottom channel of the bottle; as well as A puncture needle tube, which is longitudinally movable within the bottom channel of the bottle; The vial assembly has a fluid blocking state and a fluid communicating state. When the puncture needle does not pierce the sealing block, the puncture needle is not communicating with the drug receiving chamber, and the vial assembly is in a fluid blocking state. When the puncture needle moves longitudinally to pierce the sealing block and communicates with the drug receiving chamber, the vial assembly is in a fluid communicating state.

2. The vial assembly according to claim 1, characterized in that, The puncture needle is provided with a stop block, which is configured to restrict the longitudinal movement of the puncture needle; wherein, when the puncture needle punctures the sealing block and is in fluid communication with the drug receiving chamber, the stop block abuts against the bottle body or the sealing block.

3. The vial assembly according to claim 2, characterized in that, The bottle bottom channel includes a first cavity and a first actuation auxiliary cavity. The first cavity is located on the side of the first actuation auxiliary cavity away from the drug receiving chamber, and the inner diameter of the first cavity is smaller than the inner diameter of the first actuation auxiliary cavity. The sealing block is fixedly disposed on the upper end of the first actuation auxiliary cavity, and the stop block is longitudinally movable and arranged in the first actuation auxiliary cavity; When the puncture needle punctures the sealing block and is in fluid communication with the drug-containing chamber, the stop block abuts against the sealing block.

4. The vial assembly according to claim 3, characterized in that, The bottle bottom channel further includes a second cavity, which is disposed between the drug receiving chamber and the first actuation auxiliary chamber; the inner diameter of the second cavity is smaller than the inner diameter of the first actuation auxiliary chamber, and the first actuation auxiliary chamber is connected to the drug receiving chamber through the second cavity.

5. The vial assembly according to any one of claims 1 to 4, characterized in that, The bottom of the drug-containing chamber is constructed in a cone shape, wider at the top and narrower at the bottom.

6. A medicine bottle assembly system, characterized in that, include: The vial assembly according to any one of claims 1 to 5; and A radiation shielding assembly, comprising a shielding body and a silicone component; wherein... The shielding body has a top opening and a vial receiving cavity, and the radiation shielding assembly is configured to receive the vial within the vial receiving cavity through the top opening; The bottom of the vial receiving cavity is provided with a mating channel, which communicates with the bottle bottom channel. The mating channel includes a notch section and a receiving groove from top to bottom. The receiving groove is consistent with the shape of the silicone part, and the silicone part is seated in the receiving groove and seals the notch section. When the vial assembly and the radiation shielding assembly are in the assembled position, the vial assembly is in a fluid communication state, and the non-puncture end of the puncture needle passes through the notch section and the silicone part and extends to the bottom of the receiving groove.

7. The vial assembly system according to claim 6, characterized in that, The silicone part has a linear cut in the middle.

8. The vial assembly system according to claim 6, characterized in that, The mating channel further includes a second actuation auxiliary cavity, which is located on the lower side of the receiving groove; When the vial assembly and the radiation shielding assembly are in the assembled position, the non-puncture end of the puncture needle enters the second actuation auxiliary cavity.

9. The vial assembly system according to claim 8, characterized in that, The second actuation auxiliary cavity includes an upper cavity and a lower cavity that are longitudinally connected. The inner diameter of the upper cavity is larger than the outer diameter of the non-puncture end of the puncture needle tube, and the inner diameter of the lower cavity is smaller than the outer diameter of the non-puncture end of the puncture needle tube. When the vial assembly and the radiation shielding assembly are in the assembled position, the non-puncture end of the puncture needle abuts against the bottom of the upper cavity.

10. The vial assembly system according to claim 9, characterized in that, The bottom of the shielding body is provided with an external connection channel, which is connected to the second actuation auxiliary cavity. The outlet of the external connection channel is provided with a pipeline interface. The radiation shielding assembly also includes a straight-through valve, which is fluidly connected to the pipeline interface.